Mieloma Multiple - Mieloma.com

Mieloma Novedades en investigacion enero 2007

Fuente y mas informacion:
 Thu, 25 Jan 2007 13:07:57 -0600 (CST)
De:    "MMRF SmartBrief "
http://www.multiplemyeloma.org/


    Leukemia. 2007 Jan 18
    A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R


    Clin Lymphoma Myeloma. 2006 Nov
    Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, Meisenberg B


    Clin Lymphoma Myeloma. 2006 Nov
    Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Berenson JR, Yeh HS





____________
Guia de Uso - http://www.mieloma.com/v2/uso-del-foro-vf27.html

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.

Fuente y mas informacion:

Myeloma Minute - January 23, 2007
http://readtheminute.myeloma.org/

    *

      A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
http://www.bloodjournal.org/cgi/con...006-07-038430v1
      John D Shaughnessy, Jr, Fenghuang Zhan, Bart E Burington, Yongsheng Huang, Simona Colla, Ichiro Hanamura, James P Stewart, Bob Kordsmeier, Christopher Randolph, David R Williams, Yan Xiao, Hongwei Xu, Joshua Epstein, Elias Anaissie, Somashekar G Krishna, Michele Cottler-Fox, Klaus Hollmig, Abid Mohiuddin, Mauricio Pineda-Roman, Guido Tricot*, Frits van Rhee, Jeffrey Sawyer, Yazan Alsayed, Ronald Walker, Maurizio Zangari, John Crowley*, and Bart Barlogie*
      Blood published 14 November 2006, 10.1182/blood-2006-07-038430

    * High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
http://www.ncbi.nlm.nih.gov/entrez/...ed_ExternalLink
      Benson DM Jr, Elder PJ, Lin TS, Blum W, Penza S, Avalos B, Copelan E, Farag SS.
      Leuk Res. 2006 Oct 27; [Epub ahead of print]

    *

      A triple on AL amyloidosis, waiting for a home run
http://www.bloodjournal.org/cgi/content/full/109/2/391?etoc
      Geraldine P. Schechter
      Blood 2007;109 391-392

    * Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
http://www.bloodjournal.org/cgi/content/abstract/109/2/457?etoc
      Ashutosh D. Wechalekar, Hugh J. B. Goodman, Helen J. Lachmann, Mark Offer, Philip N. Hawkins, and Julian D. Gillmore
      Blood 2007;109 457-464

    * The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
http://www.bloodjournal.org/cgi/content/abstract/109/2/465?etoc
      Angela Dispenzieri, Martha Q. Lacy, Steven R. Zeldenrust, Suzanne R. Hayman, Shaji K. Kumar, Susan M. Geyer, John A. Lust, Jacob B. Allred, Thomas E. Witzig, S. Vincent Rajkumar*, Philip R. Greipp, Stephen J. Russell, Brian Kabat, and Morie A. Gertz*
      Blood 2007;109 465-470

    * Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
http://www.bloodjournal.org/cgi/content/abstract/109/2/492?etoc
      Vaishali Sanchorawala, Daniel G. Wright, Michael Rosenzweig, Kathleen T. Finn, Salli Fennessey, Jerome B. Zeldis, Martha Skinner, and David C. Seldin
      Blood 2007;109 492-496

    * Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts
http://www.bloodjournal.org/cgi/content/abstract/109/2/711?etoc
      Consuelo Gajate and Faustino Mollinedo
      Blood 2007;109 711-719

    * STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90{alpha} and {beta} in multiple myeloma cells, which critically contribute to tumor-cell survival
http://www.bloodjournal.org/cgi/content/abstract/109/2/720?etoc
      Manik Chatterjee, Sarika Jain, Thorsten Stuhmer, Mindaugas Andrulis, Ute Ungethum, Ralf-Jurgen Kuban, Heike Lorentz, Kurt Bommert, Max Topp, Doris Kramer, Hans Konrad Muller-Hermelink, Hermann Einsele, Axel Greiner, and Ralf C. Bargou
      Blood 2007;109 720-728

    *

      Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
http://www.bloodjournal.org/cgi/con...40410v1?papetoc
      Herve Avet-Loiseau*, Michel Attal*, Philippe Moreau, Catherine Charbonnel, Frederic Garban, Cyrille Hulin, Serge Leyvraz, Mauricette Michallet, Ibrahim Yakoub-Agha, Laurent Garderet, Gerald Marit, Lucienne Michaux, Laurent Voillat, Marc Renaud, Bernard Grosbois, Gaelle Guillerm, Lotfi Benboubker, Mathieu Monconduit, Catherine Thieblemont, Philippe Casassus, Denis Caillot, Anne-Marie Stoppa, Jean-Jacques Sotto, Marc Wetterwald, Charles Dumontet, Jean-Gabriel Fuzibet, Isabelle Azais, Veronique Dorvaux, Marc Zandecki, Regis Bataille*, Stephane Minvielle, Jean-Luc Harousseau*, Thierry Facon, and Claire Mathiot
      Blood published 5 January 2007, 10.1182/blood-2006-08-040410

    * Integrated molecular profiling of SOD2 expression in multiple myeloma
http://www.bloodjournal.org/cgi/con...35162v1?papetoc
      Elaine M Hurt, Suneetha B Thomas, Benjamin Peng, and William L Farrar
      Blood published 27 December 2006, 10.1182/blood-2006-07-035162





____________
Guia de Uso - http://www.mieloma.com/v2/uso-del-foro-vf27.html

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.

Mieloma Novedades en investigacion enero 2007

Fuente y mas informacion:
 Thu, 18 Jan 2007 12:39:56 -0600 (CST)
De:    "MMRF SmartBrief "
http://www.multiplemyeloma.org/

    Chest. 2007 Jan
    Risk of thrombosis with lenalidomide and its prevention with aspirin
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Hirsh J


    Br J Haematol. 2007 Jan
    Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Kukreja A, Hutchinson A, Mazumder A, Vesole D, Angitapalli R, Jagannath S, O'connor OA, Dhodapkar MV


    Br J Haematol. 2007 Jan 11
    Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, Westveer PH, Poddighe PJ, Verhoef GE, Sonneveld P; for the Dutch-Belgian Haemato-Oncology Cooperative Study Group and the Dutch Working Party on Cancer Genetics and Cytogenetics





____________
Guia de Uso - http://www.mieloma.com/v2/uso-del-foro-vf27.html

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.

Mieloma Novedades en investigacion enero 2007

Fuente y mas informacion:
Thu, 11 Jan 2007 12:46:06 -0600 (CST)
De:    "MMRF SmartBrief "
http://www.multiplemyeloma.org/

    Ann Hematol. 2007 Jan 5
    Towards a new age in the treatment of multiple myeloma
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Piazza FA, Gurrieri C, Trentin L, Semenzato G

    Bone Marrow Transplant. 2007 Jan
    Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D.

    Blood. 2007 Jan 9
    Targeting aurora kinases as therapy in multiple myeloma
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A





____________
Guia de Uso - http://www.mieloma.com/v2/uso-del-foro-vf27.html

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.

Mieloma Novedades en investigacion enero 2007

Fuente y mas informacion:
Thu, 4 Jan 2007 12:56:08 -0600 (CST)
De:    "MMRF SmartBrief "
http://www.multiplemyeloma.org/

    Expert Rev Anticancer Ther. 2006 Dec
    Immunotherapy of multiple myeloma: the start of a long and tortuous journey
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Harrison SJ, Cook G, Nibbs RJ, Prince HM


    Nat Clin Pract Oncol. 2007 Jan
    Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Dunstan CR, Felsenberg D, Seibel MJ


    Blood. 2006 Dec 21
    Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD Jr, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC





____________
Guia de Uso - http://www.mieloma.com/v2/uso-del-foro-vf27.html

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.

Mieloma Novedades en investigacion enero 2007

Fuente y mas informacion:
Thu, 28 Dec 2006 12:58:20 -0600 (CST)
De:    "MMRF SmartBrief "
http://www.multiplemyeloma.org/

    Curr Pharm Biotechnol. 2006 Dec
    Thalidomide in multiple myeloma
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Moehler TM, Hillengass J, Glasmacher A, Goldschmidt H

    Curr Pharm Biotechnol. 2006 Dec
    Bortezomib as an antitumor agent
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum

Roccaro AM, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A, Dammacco F, Anderson KC

    Curr Pharm Biotechnol. 2006 Dec
    Targeting pathways mediating bone disease
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Giuliani N, Morandi F, Tagliaferri S, Rizzoli V

    Curr Pharm Biotechnol. 2006 Dec
    Immunomodulatory drugs as a therapy for multiple myeloma
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
De Raeve H, Vanderkerken K

    Curr Pharm Biotechnol. 2006 Dec
    Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Zangari M, Cavallo F, Tricot G





____________
Guia de Uso - http://www.mieloma.com/v2/uso-del-foro-vf27.html

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.

Mieloma Novedades en investigacion enero 2007

Fuente y mas informacion:
Thu, 21 Dec 2006 12:29:31 -0600 (CST)
De:    "MMRF SmartBrief "
http://www.multiplemyeloma.org/

    Haematologica. 2006 Dec
    Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
Wu KL, Beksac M, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P

    J Support Oncol. 2006 Nov-Dec
    Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum
McDermott RS, Kloth DD, Wang H, Hudes GR, Langer CJ

    Acta Haematol. 2006 Dec 5
    Recombinant Human Erythropoietin Is Associated with Increased Overall Survival in Patients with Multiple Myeloma
http://www.ncbi.nlm.nih.gov/entrez/...l=pubmed_docsum

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA





____________
Guia de Uso - http://www.mieloma.com/v2/uso-del-foro-vf27.html

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.